Last reviewed · How we verify
Du-Cotecxin
Du-Cotecxin is a heparin-based anticoagulant.
Du-Cotecxin is a heparin-based anticoagulant. Used for Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery.
At a glance
| Generic name | Du-Cotecxin |
|---|---|
| Also known as | SP |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Anticoagulant |
| Target | Thrombin, Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Du-Cotecxin works by inhibiting the coagulation cascade, specifically by inactivating thrombin and factor Xa. This leads to a reduction in blood clot formation and a decrease in the risk of thrombotic events.
Approved indications
- Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery
Common side effects
- Hemorrhage
- Thrombocytopenia
Key clinical trials
- Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Du-Cotecxin CI brief — competitive landscape report
- Du-Cotecxin updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI